Development of targeted glioblastoma radiosensitizers

We have acquired isogenic cell lines and gene targeting tools from Horizon Discovery, Ltd, which will allow us to screen for GBM radiosensitizers which specifically target key mutations, such as IDH1 and PTEN. This project will begin in the summer of 2014.